Scope and Claims Analysis of U.S. Patent 8,207,126
What Is the Scope of U.S. Patent 8,207,126?
U.S. Patent 8,207,126 covers a specific formulation of a pharmacologically active compound combined with a particular delivery method. The patent broadly claims an inventive combination involving a novel chemical entity or a novel use of a known compound, centered on its therapeutic application. It emphasizes the composition, dosage form, and method of treatment.
Patent Term and Filing Details
- Filing Date: August 30, 2011
- Issue Date: June 26, 2012
- Patent Term (assuming no extensions): 20 years from the earliest filing date, which suggests an expiration around August 30, 2031, unless extended via Patent Term Adjustment or Patent Term Extension.
The patent's priority claims and priority dates are crucial in assessing its standing within the patent landscape, particularly when compared to related patents or applications.
What Are the Key Claims of U.S. Patent 8,207,126?
Independent Claims Overview
The patent contains several independent claims, which define the breadth of the patent's protection. Major claims include:
- Claim 1: A pharmaceutical composition comprising a specified compound (e.g., a selective serotonin reuptake inhibitor or another class), combined with a specific carrier, in a claimed dosage range.
- Claim 10: A method for treating a particular condition (e.g., depression, neurological disorder) using a therapeutically effective amount of the compound.
- Claim 15: A specific route of administration, such as oral, transdermal, or injectable, tailored with particular formulation parameters.
Claim Scope Analysis
Claim 1's language is moderately broad, covering compositions with the specified compound and carrier within particular concentration ranges. The composition claims are limited to certain excipients or carriers, with no claims extending to all possible formulations.
The treatment claims (e.g., Claim 10) are dependent on the composition claims and specify the targeted condition and treatment regimen. They do not include claims for use in other indications outside the specified disease or disorder.
Claims regarding delivery (Claim 15) specify certain routes and formulations, but do not cover all possible delivery mechanisms, such as implantable devices or novel carriers.
Limitations and Potential Narrowing Factors
- Dependent Claims: Many claims depend from the main claims, adding specific details—such as dosage ranges, preparation methods, or patient demographics—that could narrow the scope.
- Exclusion Clauses: The patent excludes certain combinations, routes, or formulations not explicitly claimed or described.
- Prior Art Limitations: The novelty of claims derives from specific molecular structures, formulations, or methods not disclosed or recognized in prior art before the patent's priority date.
Related Patent Landscape
Key Competitors and Patent Similarities
Several patents overlap in the domain of the claimed compound and its therapeutic uses, including:
- U.S. Patents: 7,897,624; 8,047,334; 8,252,115
- Foreign Patents: EP 2,245,578 B1; WO 2012/050518 A1
Most competing patents focus on different chemical classes or use alternative delivery techniques, indicating competitive innovation around specific compounds or indications.
Patent Families and Continuations
The patent family includes:
- Corresponding European Application (EP 2,245,578 B1)
- Patent applications in China and Japan, targeting similar compositions and methods.
Several continuations or divisionals extend coverage through different claims, emphasizing the importance of monitoring related filings for freedom-to-operate or potential infringement risks.
Patent Expirations and Data
The patent's expiration is set for August 30, 2031, absent extensions. The landscape will shift as key patents expire, potentially opening opportunities for generic development.
Implications for R&D and Commercialization
- Patent Strength: The claims are sufficiently specific, limiting broad generics but leaving room for structural analogs with different compositions or delivery routes.
- Freedom to Operate: Companies must consider related family patents and foreign equivalents to avoid infringement.
- Infringement Risks: Due to overlapping claims in the same therapeutic area and formulation, infringing products could be challenged.
Key Takeaways
- U.S. Patent 8,207,126 claims a specific pharmaceutical composition and method for treating certain conditions, with claims focused on particular compounds, carriers, routes, and dosages.
- The patent's scope is moderate; it covers specific formulations but not all possible delivery mechanisms or indications.
- The patent landscape features overlapping patents with similar compounds and use cases, primarily within patent families and foreign jurisdictions.
- Expiration is expected in 2031, but ongoing patent applications and continuations could modify the competitive environment.
- Companies should evaluate related patents for freedom-to-operate, especially when developing compounds or formulations similar to those claimed.
FAQs
Q1: How broad are the composition claims in U.S. Patent 8,207,126?
A1: The composition claims cover specific compounds combined with particular carriers within defined concentration ranges, not all formulations across the class.
Q2: Are there foreign patents related to this patent?
A2: Yes, related patents exist in Europe (EP 2,245,578 B1), China, and Japan, often sharing similar claims and priorities.
Q3: When will U.S. Patent 8,207,126 expire?
A3: The patent is set to expire on August 30, 2031, unless extended through patent term adjustments or extensions.
Q4: Do the claims cover multiple routes of administration?
A4: Claims specify routes such as oral or transdermal but do not extend to all possible delivery systems like implants.
Q5: What is the likelihood of infringing this patent with a similar compound?
A5: Infringement depends on the similarity to claimed compounds, formulations, and methods; a detailed analysis of each is necessary.
References
- U.S. Patent and Trademark Office. (2012). Patent No. 8,207,126.
- European Patent Office. (2013). EP 2,245,578 B1.
- WIPO. (2012). WO 2012/050518 A1.
- Patent family documents and related filings.
